Sponsored
As IRA price negotiations reshape the pharmaceutical landscape, leading policy experts unpack what executives need to know now to navigate pricing uncertainty, biosimilar competition, and long-term strategic risk.
Fault Lines: Business, Reputation, and the Politics Reshaping Pharma
Advertisement
Advertisement
Trending on PharmExec
1
Launch is Just the Beginning: Rare Disease Care Requires Durability
2
AstraZeneca Shares Drop Following Wainua’s Failed Heart Disease Trial
3
Novartis to Layoff 322 NJ Employees: Report
4
FDA Approves Subcutaneous Sarclisa Escena for Multiple Myeloma
5